Background
Roche Products was invited to submit evidence for this single technology appraisal for bevacizumab in March 2015.
Roche conceded that it would not be possible to demonstrate the cost effectiveness of bevacizumab for relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer. Bevacizumab cannot be given special consideration as a treatment used at the end of life because the total population eligible for treatment across all its licensed indications is too large.
NICE has therefore terminated this single technology appraisal.